Back to News
Market Impact: 0.2
ArriVent BioPharma Consensus Price Target Increased 14.29% to $25.96
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for ArriVent BioPharma was revised up 14.29% to $25.96 per share from $22.72, the estimate dated October 20, 2026. The figures are aggregate analyst targets, not a recommendation; the article provides no company operating update or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
AVBP0.25
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?